linjc16/ctgov huggingface dataset:
Emergency Department Targeted Ultrasound for the Detection of Hydronephrosis

Study Overview
=================
Brief Summary
-----------------
An Emergency Department Targeted Ultrasound (EDTU) is an ultrasound examination performed by an emergency department physician, instead of a radiologist or ultrasound technician. EDTU is intended to be a readily assessable test performed at the bedside, to quickly and safely determine the presence of a disease state; it answers a binary question, as compared to formal ultrasound imaging which seeks to determine the cause of a patient's symptoms. The objective of this study is to determine the accuracy of EDTU in patients suspected of renal colic. By demonstrating excellent test characteristics, these investigators hope that this research will be used to incorporate EDTU for hydronephrosis into standard emergency care in Canada.

Official Title
-----------------
Emergency Department Targeted Ultrasound for the Detection of Hydronephrosis

Conditions
-----------------
Urolithiasis, Ultrasonography, Hydronephrosis

Intervention / Treatment
-----------------
* Other: emergency department targeted ultrasound imaging


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Emergency Department patients Males and Females Age 16-65 Undergoing CT scan of the abdomen or formal ultrasound of the abdomen at Kingston General Hospital or Hotel Dieu Hospital in Kingston, Ontario. Exclusion Criteria: Hemodynamic instability Fever Leukocytes or nitrites on dipstick urinalysis Pregnancy Renal failure Single functioning kidney or renal transplant

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: one<br>undergo EDTU | Other: emergency department targeted ultrasound imaging<br>* bedside ultrasound performed by emergency physician to identify hydronephrosis<br>* Other names: EDTU;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnostic accuracy of EDTU |  | 1 hour | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| same measures of diagnostic accuracy in the planned subgroup of patients being investigated for suspected renal colic |  | 1 hour | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
urolithiasis, ultrasound, hydronephrosis
Clinical Impacts of Burnout Syndrome Among Anesthesiology Residents

Study Overview
=================
Brief Summary
-----------------
This study aimed to determine the relationship between burnout levels and clinical performances of anesthesiology residents.

Detailed Description
-----------------
Fifty-five second until fourth year anesthesiology residents, who were not on any mental medication treatment, were recruited consecutively and asked to fill out questionnaires which are; the Maslach Burnout Inventory (MBI) questionnaire to assess burnout levels, Best Practice Anesthesiologist questionnaire to assess positive clinical performance, Anesthesiology Residents' Self-Reported Errors and Quality of Care questionnaire to assess negative clinical performance.

Official Title
-----------------
Relationship Between Burnout Score and Clinical Performance on Anesthesiology and Intensive Therapy Residents

Conditions
-----------------
Burnout, Caregiver

Intervention / Treatment
-----------------
* Other: Burnout and Clinical performances questionnaires


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: second until fourth year anesthesiology residents not on any mental medication treatment willing to participate Exclusion Criteria: on paid leave rejected to become the sample had their shift in 24 hours prior to this study

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Positive Clinical Performances<br>Subjects show positive clinical performances regarding burnout syndrome | Other: Burnout and Clinical performances questionnaires<br>* Subjects were given questionnaires to assess burnout score and clinical performances<br>|
| Negative Clinical Performances<br>Subjects show negative clinical performances regarding burnout syndrome | Other: Burnout and Clinical performances questionnaires<br>* Subjects were given questionnaires to assess burnout score and clinical performances<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Positive clinical performance | Subjects show positive clinical performance | 1 month through study completion | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Negative clinical performance | Subjects show negative clinical performance | 1 month through study completion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
anesthesiology, burnout, clinical performances, residency
Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure

Study Overview
=================
Brief Summary
-----------------
The investigators test the hypothesis that different beta-blockers had a different influence on chemoreceptor response and lung diffusion capacity. Both could influence exercise capacity in normoxic as well as hypoxic conditions.

Official Title
-----------------
Nebivolol Versus Bisoprolol Versus Carvedilol in Heart Failure: Effects on Exercise Capacity and Hypoxia, Chemoreceptor Response, Pulmonary Function

Conditions
-----------------
Chronic Heart Failure

Intervention / Treatment
-----------------
* Drug: carvedilol
* Drug: bisoprolol
* Drug: Nebivolol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Chronic heart failure patients in stable clinical condition Exclusion Criteria: No comorbidity NYHA class IV

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Carvedilol<br> | Drug: carvedilol<br> <br> |
| Active Comparator: Bisoprolol<br> | Drug: bisoprolol<br> <br> |
| Active Comparator: Nebivolol<br> | Drug: Nebivolol<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| exercise capacity |  | two months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| lung diffusion |  | two months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
exercise, lung diffusion, hypoxia, chemoreceptor, beta-blockers, heart failure
Anti-Proteinuric Response to ACEI, ARB and Diuretics Combination.

Study Overview
=================
Brief Summary
-----------------
Determine the best strategy for proteinuria lowering in patients with proteinuria > 1 g/day receiving ACEI and ARB combination: either increase of ACEI and ARB dosage or increase of diuretic dosage.

Conditions
-----------------
Heavy Proteinuria

Intervention / Treatment
-----------------
* Drug: ramipril 5 mg + valsartan 80 mg/day,
* Drug: ramipril 10 mg + valsartan 160 mg/day,
* Drug: ramipril 5 mg + valsartan 80 mg/day + increased dosage of furosémide.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: proteinuria > 1 g/day with ramipril 5 + valsartan 80 mg/day for 2 months proteinuria changes < 50% on 3 separate dosages over 2 months. Exclusion criteria: age < 18 or > 80 years systolic BP < 110 or ≥ 140 mmHg, serum creatinine > 250 mmole/L serum creatinine increase on ramipril + valsartan > 20% intolerance to ACEI or ARB

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: ramipril 5 mg + valsartan 80 mg/day,|nan|
|Drug: ramipril 10 mg + valsartan 160 mg/day,|nan|
|Drug: ramipril 5 mg + valsartan 80 mg/day + increased dosage of furosémide.|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Proteinuria, ACEI, ARB, diuretics, blood pressure, renal failure
Fractional CO2 Laser With Topical Pentostam Treatment for Cutaneous Leishmaniasis.

Study Overview
=================
Brief Summary
-----------------
The investigators will compare the common treatment for cutaneous leishmaniasis with intra-lesional Pentostam to fractional CO2 laser with topical application of Pentostam. Outcome will be final scar appearance assesd by two dermatologist and pain measurement by VAS.

Detailed Description
-----------------
20 healthy patients diagnosed will cutaneous leishmaniasis with more than one lesion will be recruited. Half of the lesions will be treated with intra-lesional injections of Pentostam, and the other half by CO2 laser with topical application of Pentostam. Each lesion will recieve 3 treatments, one month apart between treatments. The patients will scale pain level of each treatment. Final scar appearance will be assessed by two dermatologists, without knowing what treatment was applied to each lesion.

Conditions
-----------------
Leishmaniasis

Intervention / Treatment
-----------------
* Drug: Local application pentostam
* Drug: intra-lisional pentostam
* Device: fractional CO2 laser


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Objective cutaneous leishmaniasis diagnosis. More than one Lesion Exclusion Criteria: Previous treatment Abnormal scarring

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Treatment<br>CO2 fractional laser with local application of Pentostam | Drug: Local application pentostam<br> <br> Device: fractional CO2 laser<br> <br> |
| Active Comparator: control<br>Intra-lesinal Pentostam injedction | Drug: intra-lisional pentostam<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| scar appearance | Each lesion will be photographed prior to treatment and at 6th month (Three months after last (3rd) treatment).Two dermatologist will asses each lesion outcome | At sixth month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain assessed by VAS |  | at one month, two months, and three months |
Validity of Cardiac Output Measurement Using Niccomo Device After Cardiac Surgery

Study Overview
=================
Brief Summary
-----------------
Cardiac surgery is at high risk of low cardiac output syndrome after procedure. Monitoring cardiac function, and especially cardiac output, is important to identify cardiovascular dysfunction and to introduce and adjust optimal therapies. Invasive monitor such as pulmonary arterial catheter or transpulmonary thermodilution provide precise measurements but need an invasive access to arterial and central venous route, with possible complications. Cardiographic bioimpedencemetry (Niccomo device, Imedex Corp) allows a non invasive measurement of cardiac output and some other parameters of cardiovascular function. Nevertheless, the reliability of this device has been little studied after cardiac surgery.

Official Title
-----------------
Cardiac Output Analysis by Cardiographic Impedance: a Validation Study of the Niccomo Non-invasive Monitor in Post-operative Cardiac Surgery

Conditions
-----------------
Shock, Cardiogenic, Surgery, Output, Low Cardiac

Intervention / Treatment
-----------------
* Device: Niccomo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age > 18 y/o Patients benefiting from cardiac surgery AND pulmonary arterial catheter monitoring Exclusion Criteria: Aortic regurgitation grade 3-4 Uncontrolled Hypertension (MAP > 130 mmHg) Circulatory or cardiac assistance Active pacemaker

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| cardiac surgery<br>patients benefiting from pulmonary arterial catheter monitoring after cardiac surgery | Device: Niccomo<br>* Niccomo monitoring added to pulmonary arterial catheter monitoring<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| agreement between cardiac outputs measured by Pulmonary Arterial Catheter (PAC) and Niccomo | Cardiac outputs and systolic ejection volumes are measured at 10 different time-points and agreement between the 2 devices are explored | 48 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Systolic Time Ratio | Niccomo values at 10 different time-points | 48 hours | 
| Pre-ejection Period | Niccomo values at 10 different time-points | 48 hours | 
| Velocity Index | Niccomo values at 10 different time-points | 48 hours | 
| Left Ventricular Ratio | Niccomo values at 10 different time-points | 48 hours |
Impact of COVID19 Outbreak in Cardiac Acute Care

Study Overview
=================
Brief Summary
-----------------
This registry will evaluate the impact of the COVID19 outbreak on Cardiac patients admitted in the Intensive Care Unit of the Pitie-Salpetriere Hospital in Paris, France

Detailed Description
-----------------
Registry on Characteristics and outcomes of Cardiac patients (COVID- and COVID+) hospitalized in the Intensive Care Unit of the Pitie-Salpetriere Hospital in Paris, France

Official Title
-----------------
Impact of COVID19 Outbreak in Cardiac Patients Admitted in Intensive Care Unit : the CCU-COVID19 Study

Conditions
-----------------
Acute Coronary Syndrome, Heart Failure, COVID

Intervention / Treatment
-----------------
* Other: Data collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years and older Admitted in the Cardiac Intensive Care Unit from March 20th 2020 Patient informed and having expressed his non-opposition to participate in the research Exclusion Criteria: Minor patient Patient who expressed opposition to participation in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| COVID19- Population<br>Patients without diagnosis of COVID19, as assessed by RT-PCR and CT scan | Other: Data collection<br>* Diagnostic and prognostic evaluation of cardiac patients hospitalized in CCU during the COVID-19 outbreak; patient's immune status regarding the presence of SARS-CoV-2 specific antibodies<br>|
| COVID19+ Population<br>Patients with a diagnosis of COVID19, as assessed by RT-PCR and CT scan | Other: Data collection<br>* Diagnostic and prognostic evaluation of cardiac patients hospitalized in CCU during the COVID-19 outbreak; patient's immune status regarding the presence of SARS-CoV-2 specific antibodies<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of recurrent Major Cardiovascular Events (MACE) and urgent rehospitalization |  | From admission to one year follow up | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COVID19, Acute Coronary Syndrome, Myocardial Infarction
Collection of Blood Samples From HIV Infected People

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to collect blood samples from HIV infected individuals for use in future genetic studies.

Detailed Description
-----------------
Genetic differences among people with HIV may account for differences in disease progression and response to antiretroviral therapy. The Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) was created to conduct studies in HIV infected communities and particularly in people of color, women, and injection drug users. This study will collect whole blood samples from HIV infected individuals. The samples will be used in future CPCRA studies comparing human genetic factors with clinical data from other CPCRA studies.

Official Title
-----------------
Collection and Use of Blood For Genetic and Other Related Analyses (The GENOMICS Protocol)

Conditions
-----------------
HIV Infections

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Presently participating, previously participated in, or has given informed consent for participation in a qualifying CPCRA clinical trial Signed informed consent
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Genetic Testing, Genomics, Human Genetic Factors
Daytime Profile of Salivary Progesterone

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to perform a 12-hour profile of free saliva progesterone during the luteal phase after fresh and frozen embryo transfer. If progesterone levels in saliva samples show a constant level during daytime, this non-invasive measurement can be used in future ART patients with insufficient progesterone levels who might benefit from additional exogenous progesterone supplementation.

Official Title
-----------------
Daytime Profile of Salivary Progesterone During the Mid-luteal Phase of IVF and FET Cycles

Conditions
-----------------
Infertility, Female

Intervention / Treatment
-----------------
* Diagnostic Test: Progesterone analysis in saliva


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18-45 years One or two good quality embryos for transfer on day 5. BMI >18,5 <30 kg/m² Exclusion Criteria: No good quality embryos for transfer Uterine abnormalities One ovary Oocyte donation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: IVF/FET<br> | Diagnostic Test: Progesterone analysis in saliva<br>* Analysis of salava progesterone<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Levels of free progesterone in saliva |  | 12 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical pregnancy rate | Ultrasound detected gestational sack divided with number of embryo transfer | 8 weeks | 
| Ongoing pregnancy rate | Viable pregnancy after gestational week 12+0 | 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Progesterone, Saliva, IVF, Frozen embryo transfer
Post Operative Adjuvant Chemotherapy Followed by Adjuvant Tamoxifen vs Nil for Patients With Operable Breast Cancer

Study Overview
=================
Brief Summary
-----------------
Post operative adjuvant chemotherapy followed by adjuvant Tamoxifen vs nil for patients with operable breast cancer

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Drug: Tamoxifen


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with operable breast cancer
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Tamoxifen|Tamoxifen|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| safety |  | 10 years |